NCT07467122

Exploratory Clinical Study of TCR-T for MAGE-A4-positive Mesenchymal Malignancies

Exploratory Clinical Study of TCR-T in MAGE-A4-positive Mesenchymal Malignancies

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 15 (estimated)
• Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

RATIONALE: MAGE-A4 is a cancer-testis antigen widely expressed in various mesenchymal tumors but absent in normal tissues, making it an ideal immunotherapeutic target. Given the limited effectiveness of conventional therapies in advanced mesenchymal tumors, this study seeks to explore a novel treatment approach by engineering autologous T cells with a high-affinity TCR specific for MAGE-A4. PUOPOSE: This exploratory clinical study will assess safety profiles, treatment tolerance, and preliminary antitumor activity in patients with advanced mesenchymal malignancies.

Conditions

• Advanced Mesenchymal Malignancies

Interventions

Type	Name	Description
BIOLOGICAL	TCR-T cells targeting MAGE-A4	Infusion of TCR-T cells targeting MAGE-A4 on Day 1

Timeline

• Start date: 2026-03-15
• Primary completion: 2029-12-31
• Completion: 2031-12-31
• First posted: 2026-03-12
• Last updated: 2026-03-12

Locations

1 site across 1 country: China